FDA: Miracle II Neutralizer Contaminated
Posted on: Tuesday, 6 December 2005, 18:00 CST
WASHINGTON - The Food and Drug Administration is warning consumers not to use Tedco, Inc.'s Miracle II Neutralizer products, saying the products have been contaminated by bacteria.
Using them could lead to infections, particularly in children, the elderly and people with weakened immune systems, the FDA said.
Tedco, based in West Monroe, La., markets Miracle II Neutralizer, among other things, as an eye wash and a treatment for cataracts and pink eye. But the products are not sterile, as the FDA requires for all eye treatment products, the agency said.
The company promotes the product for treatment for a range of problems, from AIDS to diaper rash, uses that have not been approved by the FDA. It also sells a gel promoted for many of the same uses.
"Contrary to such claims, recent FDA testing of Miracle II Neutralizer and Miracle II Neutralizer Gel revealed bacterial contamination and poor manufacturing conditions," the agency said.
The product is sold in stores and on the Internet. The company has declined the FDA's appeal to voluntarily remove its products from the market.
Source: Associated Press/AP Online
Related Articles
- Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight
- Genta Submits NDA Amendment to FDA for Genasense As Treatment of Chronic Lymphocytic Leukemia
- Onset Therapeutics Announces FDA Submission for Novel Product for Topical Treatment of Genital Warts
- FDA Approves the Allergy Treatment Zyrtec(R) for Use Without a Prescription
- AstraZeneca Gets FDA Nod for Maintenance Treatment of Schizophrenia
- Taxotere(R) (Docetaxel) Granted FDA Priority Review for Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck Prior to Chemoradiotherapy and Surgery
- FDA Approves Norditropin(R)for Treatment of Short Stature Associated With a Rare Genetic Disorder
- FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
- St. Francis Medical Technologies Announces National Availability of First and Only FDA Approved, Non-Fusion Treatment for Common Degenerative Spine Disorder
- Teva and Active Biotech Announce the Submission of an IND to the FDA for Laquinimod, an Oral Product for the Treatment of Relapsing MS
 |
 |
User Comments (0)
RSS Feeds